Author: PAUL WISEMAN
These tariffs – which can run as high as 50% — are meant to punish countries for trade barriers that Trump says unfairly limit U.S. exports and cause it to run huge trade deficits. Even countries with which the U.S. enjoys trade surpluses – meaning it sells to them more than it buys, such as the United Kingdom and Argentina – are being targeted with a minimum tariff of 10%. And the highest tariffs are landing on two tiny territories that trade little with America — the African kingdom of Lesotho and the French possession of Saint Pierre and Miquelon…
Investment Supports Education, Research at St. John Center for Translational Engineering and MedicineRead More
3D printing, space navigation, and human research filled the science schedule aboard the International Space Station on Thursday. The Expedition 72 crew members are helping researchers plan missions farther away from Earth with less support from mission controllers.Read More
Mark Mahaney, Evercore ISI managing partner, discusses how the global reaction to tariffs is rattling tech stocks. He joins Caroline Hyde on “Bloomberg Technology.” (Source: Bloomberg)Read More
Tariff news knocked more than $300 billion off Apple’s market cap on Thursday.Read More
Bloomberg Technology is the only daily news program focused exclusively on technology, innovation and the future of business.Read More
Stocks plummeted on Thursday in reaction to a widening global trade war. With few parallels in history, markets are wondering where things go from here.Read More
Is the trade war Trump’s strategy to bring down interest rates?Read More
Temu always lures me with its cheap junk. I love it. (Seriously.) Will tariffs make this my last dance with the sweet, sweet bargain-basement prices?Read More
Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readoutsRead More